GSK boss to address bribery scandal

GlaxoSmithKline chief executive Andrew Witty will detail what action the drugmaker is taking in response to allegations of bribery against it in China when he presents quarterly results on Wednesday, according to sources.

Chinese authorities are investigating GSK deals with travel agencies worth up to 3bn yuan (€372m) that they allege were used to facilitate bribes. The scale of the payments has fuelled debate as to whether GSK surveillance systems were up to the job of spotting wrongdoing.

Although an internal company investigation has yet to conclude, sources said Witty would discuss what may have gone wrong in the scandal, which has rocked GSK’s reputation and left its management in China in disarray.